AbbVie announced positive Phase 2 trial results for mirvetuximab soravtansine-gynx combined with carboplatin in treating platinum-sensitive ovarian cancer patients expressing folate receptor alpha. The trial showed a 62.7% objective response rate and manageable safety profile, with many patients continuing on monotherapy. This treatment shows promise especially for patients previously treated with PARP inhibitors, who often face resistance to standard therapies. Further studies are expected to confirm these findings and potentially expand treatment options for ovarian cancer.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
